CHARLOTTESVILLE, VA (May 22, 2012) – Edward D. Miller, MD, chief executive officer of Johns Hopkins Medicine, a $6.5 billion integrated global health enterprise and one of the nation’s premier health care systems, has been elected to the Board of Directors of the Focused Ultrasound Foundation. Dr. Miller is also dean of The Johns Hopkins University School of Medicine and serves as the university’s vice president for medicine.
“We are honored to welcome Dr. Miller to our Board of Directors,” said Neal F. Kassell, MD, chairman of the Focused Ultrasound Foundation. “The perspective, insights and experience he offers as CEO of one of the world’s most prestigious and successful healthcare systems will be invaluable in helping the Foundation advance focused ultrasound therapies into mainstream clinical use.”
Dr. Miller’s tenure as the first CEO of Johns Hopkins Medicine began in 1997. Since then, he has overseen a massive renovation of the medical campus in Baltimore, Maryland, the development of an integrated regional health care delivery system and the establishment of relationships with hospitals and healthcare-related institutions in more than a dozen countries. The Maryland Senate and House of Delegates recently passed resolutions acknowledging Dr. Miller’s extraordinary vision, significant accomplishments and exemplary leadership during the past 15 years.
“I am very impressed with the worldwide progress the Foundation has made in advancing the science of focused ultrasound therapy in just a few short years,” Dr. Miller said. “Being elected to its Board of Directors is an honor. I look forward to contributing to the revolutionary work the Foundation has initiated to provide a new generation of noninvasive therapies that may save and improve the lives of millions of people around the world.”
About Focused Ultrasound
An early-stage medical technology with the potential to revolutionize the treatment of many life threatening and disabling conditions, focused ultrasound uses concentrated acoustic energy to treat tissue deep in the body while leaving surrounding healthy areas intact. Potentially, focused ultrasound could be a breakthrough in noninvasive surgery, serve as an alternative or complement to radiation therapy and enable the delivery of drugs at high concentrations to precise targets with less systemic toxicity. Researchers around the world are investigating the technology’s use in treating many forms of cancer – including bone, brain, breast, liver, pancreas, prostate and thyroid – and neurological conditions such as essential tremor, Parkinson’s disease, epilepsy, obsessive compulsive disorder and stroke. In the United States, focused ultrasound treatment for uterine fibroids has been approved by the FDA. Other approved indications are available abroad.
About the Focused Ultrasound Foundation
Based in Charlottesville, Virginia, the Focused Ultrasound Foundation was created improve the lives of millions of people worldwide by accelerating the development and adoption of focused ultrasound. The Foundation works to clear the path to global adoption of focused ultrasound by coordinating and funding research and education, creating partnerships and fostering collaboration among stakeholders, and building awareness of “medicine’s best kept secret.”
The Foundation is dedicated to ensuring that focused ultrasound finds its place as a mainstream therapy for benign and malignant tumors, neurological disorders and other serious medical conditions within years, not decades. Since its establishment in 2006, the Foundation has become the largest non-governmental source of funding for focused ultrasound research. Additional information about the Foundation can be found online at www.fusfoundation.org
Ellen C. McKenna